ReviewInternational journal of molecular sciences2025
Integrating Bioprinting and Increased Throughput: Next-Generation Models for Cardiac Research.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two decades, three-dimensional cell culture (3DCC) and bioprinting (3DBP) technology have been at the forefront of developing engineered human cardiac tissue. Compared to 2D culture systems, 3DCC-based models more accurately replicate key characteristics of living tissues such as diffusion dynamics, interactions between cells and the extracellular matrix, as well as the presence of supporting stromal components. The rise of new 3DBP techniques serves to facilitate the robust and rapid generation of 3D tissue alongside real-time assessment of their characteristics. In order to capitalize on their translational potential, high-throughput screening (HTS) is required as research draws nearer to replicating clinical trials with cardiovascular-bioprinted tissues, and testing for the safety and efficacy of novel therapeutics. In this review, we summarize trending cardiac tissue models, as well as the state of their related or integrated HTS process and development. With an emphasis on the need for scale-up, compatibility, and standardization in HTS, the coalescence of 3DBP models and screening can provide improved disease modeling, drug efficacy, and toxicity testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.